2011年临床肿瘤学十二大进展

1. Lung cancer deaths reduced by low-dose computed tomography (CT) scanning of people at high risk

    低剂量螺旋CT筛查降低肺癌死亡率（N Engl J Med. 2011:365:395-409）安徽省立医院肿瘤科何义富

2. Crizotinib (Xalkori) approved for rare type of lung cancer in August 2011 by the US Food and Drug Administration (FDA).

  克里唑蒂尼胶囊批准应用于肺癌（间变性淋巴瘤激酶（ALK）阳性）

3.Exemestane (Aromasin) reduced risk for breast cancer in high-risk postmenopausal women in the MAP.3 (Mammary Prevention Trial).

 依西美坦降低高危绝经后妇女乳腺癌风险（N Engl J Med. 2011:364:2381-2391）

4.In early breast cancer, adding regional nodal irradiation decreases recurrences

     1-3个淋巴结或淋巴结阴性的高危早期乳腺癌

5.Vemurafenib (Zelboraf) improves survival in advanced melanoma in patients with BRAF mutations, compared with standard chemotherapy (New Engl J Med. 2011;364:2507-2516).

6.First-line ipilimumab (Yervoy) plus chemotherapy improves survival in metastatic melanoma in a phase 3 study (N Engl J Med. 2011;364:2517-2526

7，8.Bevacizumab (Avastin) has been shown to delay progression in both recurrent and newly diagnosed ovarian cancer in 2 separate phase 3 trials

9.A new high-dose chemotherapy regimen improves survival in neuroblastoma

   an intense dosing with busulphan plus melphalan

10.A new chemotherapy regimen boosts event-free survival in acute lymphoblastic leukemia (ALL).

11. Imatanib (Gleevec) for 3 years improves survival in patients with high-risk gastrointestinal stromal tumors

12. Abiraterone acetate (Zytiga) was approved for prostate cancer in April by the FDA